Gynecological cancers remain a major threat to women's health, with traditional therapies often having limited effect and ...

多肽偶联药物是精准肿瘤治疗领域中极具前景的创新药物类型之一。PDCs与抗体偶联药物（ADCs）基于相同原理，即通过靶向载体递送细胞毒性药物。不同之处在于，PDCs采用短小、可合成的肽链替代大型抗体。这些细胞靶向肽（CTPs）分子量仅为数千道尔顿，赋予 ...

Chong Kun Dang recently announced plans to invest 2.2 trillion Korean won to establish a state-of-the-art biopharmaceutical complex research and development site in the Baegot District of Siheung City ...

Company has initiated Phase 1 study with STRO-004, its potential best-in-class Tissue Factor ADC - - Sutro has selected PTK7 as the target for its initial dual-payload candidate, STRO-227 - - Investor ...

IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for antibody–drug conjugates (ADCs), and Xcellon Biologics, a U.S.-based contract ...

The Doodle shows how the parabola changes with different numbers, making learning math fun and interactive for students.,, ...

"I just liked working with them so much that I joined them," Chen told BioWorld. Today, Chen is co-CEO of WuXi AppTec. The company, which started with a laboratory of 7,000 square feet, has grown into ...

To help bridge that gap, Morrisville-based Kymanox Corporation has entered into a non-exclusive collaboration with Jabil Inc., which is based in St. Petersburg, Florida, to support companies ...

“Our investment in the Durham laboratory services facility reflects Alcami’s dedication to scientific excellence, innovation, and operational agility,” said Katie Schlipp, President of Laboratory ...

Please provide your email address to receive an email when new articles are posted on . The most common ocular adverse events with antibody-drug conjugates involve the ocular surface. The mainstay of ...